ATHLONE, Ireland -- The Board of Innocoll Holdings plc (“Innocoll” or the “Company”) (NASDAQ:INNL) notes anomalous movements in Innocoll’s share price this week and confirms that it is in discussions which may or may not lead to an offer for the entire issued share capital of the Company.
Management has been investigating and continues to investigate strategic options for the Company to maximise shareholder value. There can be no certainty that this will lead to an offer for Innocoll or any of its share capital nor as to the terms on which an offer, if any, might be made. The Company has participated in a Type A meeting with the United States Food and Drug Administration ("FDA") regarding the re-submission to the FDA for approval of XARACOLL. It expects to receive the minutes of the Type A meeting before the end of March and will make a further announcement at that time.
A further announcement will be made when appropriate.
ENQUIRIES
Innocoll Holdings plc
Jose (Pepe) Carmona, Chief Financial Officer
pcarmona@innocoll.com
Piper Jaffray & Co
Peter Day, Managing Director
Peter.c.day@pjc.com
Peter Lombard, Managing Director
peter.a.lombard@pjc.com
Michael Burton-Williams, Principal
michael.g.burton-williams@pjc.com